2024-04-01 2025-03-31 false Capium Accounts Production 1.1 04499318 2024-04-01 2025-03-31 04499318 bus:FullAccounts 2024-04-01 2025-03-31 04499318 bus:FRS102 2024-04-01 2025-03-31 04499318 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 04499318 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 04499318 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 04499318 2024-04-01 2025-03-31 04499318 2025-03-31 04499318 bus:RegisteredOffice 2024-04-01 2025-03-31 04499318 core:WithinOneYear 2025-03-31 04499318 core:AfterOneYear 2025-03-31 04499318 1 2024-04-01 2025-03-31 04499318 bus:Director1 2024-04-01 2025-03-31 04499318 bus:Director1 2025-03-31 04499318 bus:Director1 2023-01-01 2024-03-31 04499318 bus:Director2 2024-04-01 2025-03-31 04499318 bus:Director2 2025-03-31 04499318 bus:Director2 2023-01-01 2024-03-31 04499318 bus:Director3 2024-04-01 2025-03-31 04499318 bus:Director3 2025-03-31 04499318 bus:Director3 2023-01-01 2024-03-31 04499318 bus:Director4 2024-04-01 2025-03-31 04499318 bus:Director4 2025-03-31 04499318 bus:Director4 2023-01-01 2024-03-31 04499318 bus:Director5 2024-04-01 2025-03-31 04499318 bus:Director5 2025-03-31 04499318 bus:Director5 2023-01-01 2024-03-31 04499318 2023-01-01 04499318 2023-01-01 2024-03-31 04499318 2024-03-31 04499318 core:WithinOneYear 2024-03-31 04499318 core:AfterOneYear 2024-03-31 04499318 bus:EntityAccountantsOrAuditors 2023-01-01 2024-03-31 04499318 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 04499318 bus:OrdinaryShareClass1 2025-03-31 04499318 bus:OrdinaryShareClass1 2023-01-01 2024-03-31 04499318 bus:OrdinaryShareClass1 2024-03-31 04499318 core:CostValuation core:Non-currentFinancialInstruments 2025-03-31 04499318 core:CostValuation core:Non-currentFinancialInstruments 2024-03-31 04499318 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-03-31 04499318 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-03-31 04499318 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-03-31 04499318 core:Non-currentFinancialInstruments 2025-03-31 04499318 core:Non-currentFinancialInstruments 2024-03-31 04499318 core:ShareCapital 2025-03-31 04499318 core:ShareCapital 2024-03-31 04499318 core:SharePremium 2025-03-31 04499318 core:SharePremium 2024-03-31 04499318 core:RetainedEarningsAccumulatedLosses 2025-03-31 04499318 core:RetainedEarningsAccumulatedLosses 2024-03-31 04499318 dpl:Item1 2024-04-01 04499318 dpl:Item1 2025-03-31 04499318 dpl:Item1 2023-01-01 04499318 dpl:Item1 2024-03-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 04499318
England and Wales

 

 

 

C4L LABORATORY SERVICES LTD



Unaudited Financial Statements
 


Period of accounts

Start date: 01 April 2024

End date: 31 March 2025
Directors W Channon
Dr J Drew
D Channon
Dr L A Martin-Drew
C E Rees
Registered Number 04499318
Registered Office Units 2 and 3 Oak House
Albert Drive
Burgess Hill
West Sussex
RH15 9TN
Accountants OMB Tax Limited
Unit 10, Clayfield Mews
Newcomen Road
Tunbridge Wells
TN4 9PA
1
 
 
Notes
 
2025
£
  2024
£
Fixed assets      
Investments 3 1,518,320    1,434,556 
1,518,320    1,434,556 
Current assets      
Debtors 4 1,746,658    1,813,968 
Cash at bank and in hand 6,420    12,280 
1,753,078    1,826,248 
Creditors: amount falling due within one year 5 (25,595)   (26,173)
Net current assets 1,727,483    1,800,075 
 
Total assets less current liabilities 3,245,803    3,234,631 
Creditors: amount falling due after more than one year 6 (3,039,566)   (3,028,394)
Net assets 206,237    206,237 
 

Capital and reserves
     
Called up share capital 7 7,269    7,269 
Share premium account 8 97,799    97,799 
Profit and loss account 101,169    101,169 
Shareholders' funds 206,237    206,237 
 


For the year ended 31 March 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:
  1. The members have not required the Company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the board of directors on 29 December 2025 and were signed on its behalf by:


-------------------------------
W Channon
Director
2
General Information
C4L Laboratory Services Ltd is a private company, limited by shares, registered in England and Wales, under 04499318, at Units 2 and 3 Oak House, Albert Drive, Burgess Hill, West Sussex, RH15 9TN.  The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including the provisions of Section 1A "Smaller Entities" and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared on the going concern basis and under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the Company.
Going concern basis
The directors believe that the company is experiencing good levels of sales growth and profitability, and that it is well placed to manage its business risks successfully. Accordingly, they have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements.
Taxation
Taxation represents the sum of tax currently payable and deferred tax.  Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The Company's liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.  Current and deferred tax assets and liabilities are not discounted
Fixed asset investments
The Fixed asset investment represents an involvement in an associated LLP.   The value of the involvement in stated in the balance sheet at cost.
2.

Average number of employees

Average number of employees during the year was 25 (2024 : 25).
3.

Investments

Cost Other investments other than loans   Total
  £   £
At 01 April 2024 1,434,556    1,434,556 
Additions 83,764    83,764 
Disposals  
At 31 March 2025 1,518,320    1,518,320 

4.

Debtors: amounts falling due within one year

2025
£
  2024
£
Loan to LLP 166,870    166,870 
CyteTech Limited 1,052,275    996,304 
The Parents Class Limited   66,095 
UAE Labs 57,186    57,186 
Other Debtors 470,327    527,513 
1,746,658    1,813,968 

5.

Creditors: amount falling due within one year

2025
£
  2024
£
Taxation and Social Security 26,759    26,298 
Other Creditors (1,164)   (125)
25,595    26,173 

6.

Creditors: amount falling due after more than one year

2025
£
  2024
£
Other Creditors 3,039,566    3,028,394 
3,039,566    3,028,394 

7.

Share Capital

Allotted, called up and fully paid
2025
£
  2024
£
726,900 Ordinary shares of £0.01 each 7,269    7,269 
7,269    7,269 

8.

Share premium account

2025
£
  2024
£
Equity Share Premium b/fwd 97,799    97,799 
97,799    97,799 

3